1. Home
  2. BCDA vs NWGL Comparison

BCDA vs NWGL Comparison

Compare BCDA & NWGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$1.06

Market Cap

14.1M

Sector

Health Care

ML Signal

HOLD

Logo Nature Wood Group Limited

NWGL

Nature Wood Group Limited

HOLD

Current Price

$1.36

Market Cap

12.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCDA
NWGL
Founded
N/A
2008
Country
United States
Macau
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
12.1M
IPO Year
2009
2022

Fundamental Metrics

Financial Performance
Metric
BCDA
NWGL
Price
$1.06
$1.36
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
265.0K
1.4M
Earning Date
05-13-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$479,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.19
52 Week High
$1.80
$1.98

Technical Indicators

Market Signals
Indicator
BCDA
NWGL
Relative Strength Index (RSI) N/A 56.67
Support Level N/A $1.10
Resistance Level N/A $1.45
Average True Range (ATR) 0.00 0.29
MACD 0.00 -0.02
Stochastic Oscillator 0.00 35.79

Price Performance

Historical Comparison
BCDA
NWGL

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About NWGL Nature Wood Group Limited

CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.

Share on Social Networks: